Skip to main content

CORRECTION article

Front. Pharmacol., 11 December 2024
Sec. Neuropharmacology

Corrigendum: Edaravone dexborneol treatment attenuates neuronal apoptosis and improves neurological function by suppressing 4-HNE-associated oxidative stress after subarachnoid hemorrhage

  • The Second Affiliated Hospital, Brain Science Institute, School of Basic Medical Sciences of Shandong First Medical University and Shandong Academy of Medical Sciences, Taian, China

A Corrigendum on
Edaravone dexborneol treatment attenuates neuronal apoptosis and improves neurological function by suppressing 4-HNE-associated oxidative stress after subarachnoid hemorrhage

by Chen Q, Cai Y, Zhu X, Wang J, Gao F, Yang M, Mao L, Zhang Z and Sun B (2022). Front. Pharmacol. 13:848529. doi: 10.3389/fphar.2022.848529

In the published article, there was an error in Supplementary Image 1. The inclusion of multiple brain images in the figure led to a typesetting oversight, resulting in the duplication of two brain images within the PBS and Eda Dexborneol groups. The correct Supplementary Image 1 is now published with the published article.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: oxidative stress, subarachnoid hemorrhage, edaravone dexborneol, 4-HNE, edaravone

Citation: Chen Q, Cai Y, Zhu X, Wang J, Gao F, Yang M, Mao L, Zhang Z and Sun B (2024) Corrigendum: Edaravone dexborneol treatment attenuates neuronal apoptosis and improves neurological function by suppressing 4-HNE-associated oxidative stress after subarachnoid hemorrhage. Front. Pharmacol. 15:1508703. doi: 10.3389/fphar.2024.1508703

Received: 09 October 2024; Accepted: 20 November 2024;
Published: 11 December 2024.

Edited and reviewed by:

Rui Liu, Chinese Academy of Medical Sciences and Peking Union Medical College, China

Copyright © 2024 Chen, Cai, Zhu, Wang, Gao, Yang, Mao, Zhang and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Leilei Mao, bGVpbGVpLTAzMThAMTYzLmNvbQ==; Zongyong Zhang, enl6aGFuZ0BzZGZtdS5lZHUuY24=; Baoliang Sun, YmxzdW44OEAxNjMuY29t

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.